A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease
| Autor: | Roy Sherwood, Savvas Papagrigoriadis, Ana Nora Donaldson, Charlotte Kvasnovsky, Ingvar Bjarnason |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pharmacology
medicine.medical_specialty Abdominal pain business.industry Immunology Placebo-controlled study Placebo Gastroenterology 03 medical and health sciences 0302 clinical medicine Bloating 030220 oncology & carcinogenesis Internal medicine Back pain medicine Diverticular disease Clinical endpoint Dysuria 030211 gastroenterology & hepatology Pharmacology (medical) medicine.symptom business |
| Zdroj: | Inflammopharmacology. |
| ISSN: | 1568-5608 |
| Popis: | Diverticular disease is a significant burden on healthcare systems that is managed, surgically or medically, mainly as an emergency or acute condition. There are no standardized treatment recommendations for symptomatic uncomplicated disease. We hypothesized that a probiotic would reduce abdominal pain in such patients. We conducted a single-center, double-blind, placebo-controlled trial of probiotic treatment (Symprove) in adult patients with moderate-to-severe chronic, non-acute symptomatic diverticular disease. 143 patients were randomized to receive 1 mL/kg/day of probiotic liquid (N = 72) or placebo (N = 71) daily for 3 months. The primary endpoint was abdominal pain severity. Secondary endpoints consisted of the change in the frequency of eight abdominal symptoms and the level of intestinal inflammation (fecal calprotectin). 120 patients completed the trial. Abdominal pain score, the primary end point, decreased in both groups, but no significant difference between the groups was found (P = 0.11). In relation to placebo, the probiotic significantly decreased the frequency of four of the eight secondary endpoints: constipation, diarrhea, mucorrhea, and back pain (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink